Detlev Hecker, PhD | Authors

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

April 01, 1997

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in